{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.3","upperLimit":"63.5","value":"53.5"},{"groupId":"OG001","lowerLimit":"3.6","upperLimit":"41.4","value":"16.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Investigator-Assessed Intracranial Objective Response Rate (ORR) per modified RECIST 1.1 criteria is defined as the number of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of treated participants.","dispersionType":"95% Confidence Interval","groups":[{"description":"Asymptomatic patients treated with Nivolumab IV 1 mg/kg Q3W + Ipilimumab IV 3 mg/kg Q3W for a total of 4 doses of the combination therapy followed by Nivolumab IV 3 mg/kg BID for a maximum of 24 months or until progression or until unacceptable toxicity.","id":"OG000","title":"Cohort A"},{"description":"Symptomatic patients treated with Nivolumab IV 1 mg/kg Q3W + Ipilimumab IV 3 mg/kg Q3W for a total of 4 doses of the combination therapy followed by Nivolumab IV 3 mg/kg BID for a maximum of 24 months or until progression or until unacceptable toxicity.","id":"OG001","title":"Cohort B"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"Up to 66 months","title":"Intracranial Objective Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}